The U.S. Food and Drug Administration (FDA) this month approved an expanded indication for Bristol-Myers Squibb's daclatasvir (Daklinza) and Gilead Sciences sofosbuvir (Sovaldi) for additional patient groups including people with HIV/HCV coinfection, patients with advanced liver cirrhosis, and liver transplant recipients.
